$CGEN

CGEN Q2'26 Earnings: EPS estimate is (0.08) USD

Compugen Ltd. (CGEN) is scheduled to report Q2’26 results on Aug. 3 before market open, with release at 7:00 AM ET. The consensus estimates cited for Q2’26 are revenue of $1.28 million and EPS of -$0.08. The article references the company’s financials page for details.

Original reporting
Published Jul 31, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CGEN Q2'26 Earnings: EPS estimate is (0.08) USD — source image
Decision brief

The 30-second read

$CGENNeutralMed
01

Why it matters

Traders can use the stated consensus revenue ($1.28M) and EPS (-$0.08) to frame whether the upcoming print is likely to surprise and how to position into the event.

02

Market read

This is an earnings timing and consensus-expectations preview that can inform event-driven positioning and options implied-volatility expectations.

03

What to watch

The preview lacks guidance details, cash/burn commentary, and any pipeline or trial updates, which are often the real drivers of post-earnings repricing.

Relevance 6/10Novelty 5/10Timing: ahead of Aug 03 pre-market earnings release

Background

Compugen (CGEN) is set to announce Q2'26 results on Aug 03 at 7:00 AM ET (11:00 AM UTC).

Company-level read

Ticker impact

$CGENNeutralMedium confidence
Context

CGEN is scheduled to report Q2'26 results Aug 03 before the open, with consensus revenue of $1.28M and EPS of -$0.08.

Expected impact

Likely elevated pre-earnings volatility around Aug 03, with direction dependent on whether reported results beat or miss the -$0.08 EPS and $1.28M revenue expectations.

Evidence & confidence

This is a forward-looking earnings preview with specific consensus numbers, which can drive positioning and implied volatility into the print, but it does not include any new post-release datapoint.

Market effects

Biotech/small-cap earnings calendar risk for oncology/biopharma names, but no sector-wide new information is disclosed.

Primarily US pre-market positioning around a single small-cap earnings event.

Limited, as the article is company-specific and does not cite global regulatory or macro catalysts.

Counterpoint

Negative consensus EPS does not guarantee downside; if expectations are already low, a modest beat could still trigger a relief rally.

Key entities

  • CGEN

    Compugen Ltd., scheduled to report Q2'26 results before market open on Aug 03.

Related articles

$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

$HMNMed

Horace Mann Educators Q2 Earnings Call Highlights

Horace Mann (NYSE:HMN) reported Q2 call highlights. Management said auto frequency and severity trends were favorable and liability losses mid-single digits. It cut its full-year catastrophe-loss assumption to about $75M from $90M, while lowering total net investment income outlook to $465M-$475M. Revenue rose 8% YoY; life sales +20%.

$MURMedAI 8/10

Murphy Oil Sees Sharp Profit Increase

Murphy Oil Corp reported Q2 2026 adjusted net income of $225.8 million, nearly six times Q2 2025, as higher oil prices offset lower production and weaker gas. Adjusted EPS was $1.55 vs $1.51 consensus. Revenue rose to $926.3 million. Murphy kept its $0.35 dividend and raised 2026 capex midpoint to $1.55 billion.

$GSBDMed

Goldman Sachs BDC Q2 Earnings Call Highlights

Goldman Sachs BDC (NYSE:GSBD) reported no incentive fee in Q2, citing its three-year total-return lookback provision. NAV was $12.06/share at June 30 vs $12.17 in Q1. The board declared a Q3 base dividend of $0.32/share plus $0.03 supplemental. Investments were $3.2B fair value, non-accrual 2.9%, and net debt-to-equity 1.35x.

$HBBMed

Hamilton Beach Brands Q2 Earnings Call Highlights

Hamilton Beach Brands (HBB) reported Q2 gross margin of 26.1% excluding tariff-related benefits, and said it expects 2026 revenue growth in the mid-single-digit range. Management forecast full-year gross margin to improve modestly and operating profit to decline by a high-single-digit percentage. Operating cash flow is expected at $35M to $45M. HBB ended with net cash of $51.5M.